Atrial Fibrillation
This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of atrial fibrillation, which is associated with increased rates of stroke, heart failure, and mortality, in US adults.
Related Articles
Independent Physician Associations — A Bulwark against Corporate Control? | NEJM
Recent legal and regulatory uncertainty has led to concerns about the long-term viability and efficacy of certain types of physician-led health care structures as an…
5-Star Review of Remington and Klein’s Infectious Diseases of the Fetus and Newborn Infant, 9th Edition – The Bookmark
This book is a comprehensive reference book covering the fetal and neonatal aspects of immunology and infectious diseases from a global perspective.
Necrotic Plaque in a Patient With Malignant Hematologic Disease
A man in his 70s with myelodysplastic syndrome presented with a painful violaceous eruption on his left lower leg accompanied by low-grade fever and fatigue…
Government Funding for the Development of Enzalutamide
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
Bilateral Retinal Nerve Fiber Layer Thickening in a Middle-Aged Woman
A middle-aged Hispanic woman presented for evaluation of an asymptomatic epiretinal membrane in the left eye. She had an ocular history of amblyopia in the…
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.
Public employers grapple with Medicare Advantage rate hikes
Most large employers with retiree health benefit plans used Medicare Advantage this year, more than double the share in 2016.
Opinion | Remote Work Is Increasingly for The Rich
Remote work is increasingly a right exclusively enjoyed by the most affluent Americans.
How little-noticed measures to help kids with cancer became a major line of attack on GOP spending bill
President-elect Trump and Elon Musk killed the funding bill, taking the health policies with it.
Lilly’s weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to…
